Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines
Dean Johnston, Bushra Zaidi, Jean‐Claude Bystryn
Cancer Immunology Immunotherapy (2006) Vol. 56, Iss. 8, pp. 1133-1141
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

The perfect mix: recent progress in adjuvant research
Bruno Guy
Nature Reviews Microbiology (2007) Vol. 5, Iss. 7, pp. 396-397
Closed Access | Times Cited: 608
Unmet needs in modern vaccinology
Geert Leroux‐Roels
Vaccine (2010) Vol. 28, pp. C25-C36
Closed Access | Times Cited: 288
Particulate vaccines: on the quest for optimal delivery and immune response
Marie‐Luce De Temmerman, Joanna Rejman, Jo Demeester, et al.
Drug Discovery Today (2011) Vol. 16, Iss. 13-14, pp. 569-582
Open Access | Times Cited: 277
Liposome and immune system interplay: Challenges and potentials
Fahimeh Zahednezhad, Maryam Saadat, Hadi Valizadeh, et al.
Journal of Controlled Release (2019) Vol. 305, pp. 194-209
Closed Access | Times Cited: 211
Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists
Matthew Black, Amanda Trent, Matthew Tirrell, et al.
Expert Review of Vaccines (2010) Vol. 9, Iss. 2, pp. 157-173
Open Access | Times Cited: 185
Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines
Stacey L. Demento, Alyssa Siefert, Arunima Bandyopadhyay, et al.
Trends in biotechnology (2011) Vol. 29, Iss. 6, pp. 294-306
Open Access | Times Cited: 165
Protein-based nanoparticles in cancer vaccine development
Medea Neek, Tae‐il Kim, Szu‐Wen Wang
Nanomedicine Nanotechnology Biology and Medicine (2018) Vol. 15, Iss. 1, pp. 164-174
Open Access | Times Cited: 148
Engagement of TLR signaling as adjuvant: Towards smarter vaccine and beyond
Amit Lahiri, Priyanka Das, Dipshikha Chakravortty
Vaccine (2008) Vol. 26, Iss. 52, pp. 6777-6783
Closed Access | Times Cited: 140
In Vitro Analysis of Acetalated Dextran Microparticles as a Potent Delivery Platform for Vaccine Adjuvants
Eric M. Bachelder, Tristan T. Beaudette, Kyle E. Broaders, et al.
Molecular Pharmaceutics (2010) Vol. 7, Iss. 3, pp. 826-835
Open Access | Times Cited: 125
Liposomes as Adjuvants and Vaccine Delivery Systems
Daria Tretiakova, Е. Л. Водовозова
Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology (2022) Vol. 16, Iss. 1, pp. 1-20
Open Access | Times Cited: 64
Selection of Adjuvants for Enhanced Vaccine Potency
Wei Wang, Manmohan Singh
World Journal of Vaccines (2011) Vol. 01, Iss. 02, pp. 33-78
Open Access | Times Cited: 85
TLR Agonists Promote Marginal Zone B Cell Activation and Facilitate T-Dependent IgM Responses
Anatoly V. Rubtsov, Cristina L. Swanson, Scott Troy, et al.
The Journal of Immunology (2008) Vol. 180, Iss. 6, pp. 3882-3888
Open Access | Times Cited: 92
Potential adjuvantic properties of innate immune stimuli
Hemamali J. Warshakoon, Jennifer D. Hood, Matthew R. Kimbrell, et al.
Human Vaccines (2009) Vol. 5, Iss. 6, pp. 381-394
Open Access | Times Cited: 78
Clinical investigations of Toll-like receptor agonists
Thomas Meyer, Eggert Stockfleth
Expert Opinion on Investigational Drugs (2008) Vol. 17, Iss. 7, pp. 1051-1065
Closed Access | Times Cited: 77
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection
Patricia A. Taylor, Michael Ehrhardt, Christopher J. Lees, et al.
Blood (2008) Vol. 112, Iss. 8, pp. 3508-3516
Open Access | Times Cited: 75
Adjuvants for foot-and-mouth disease virus vaccines: recent progress
Yimei Cao
Expert Review of Vaccines (2014) Vol. 13, Iss. 11, pp. 1377-1385
Closed Access | Times Cited: 37
MDA5 Can Be Exploited as Efficacious Genetic Adjuvant for DNA Vaccination against Lethal H5N1 Influenza Virus Infection in Chickens
Matthias Liniger, Artur Summerfield, Nicolas Ruggli
PLoS ONE (2012) Vol. 7, Iss. 12, pp. e49952-e49952
Open Access | Times Cited: 35
Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model
Simone Vecchi, Simone Bufali, Tetsuo Uno, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2014) Vol. 87, Iss. 2, pp. 310-317
Closed Access | Times Cited: 34
Resiquimod and polyinosinic–polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine
Chun‐Xue Zhou, Li Dong, Yingli Chen, et al.
BMC Veterinary Research (2014) Vol. 10, Iss. 1
Open Access | Times Cited: 31
Innate immune control of nucleic acid-based vaccine immunogenicity
Shohei Koyama, Cevayir Coban, Taiki Aoshi, et al.
Expert Review of Vaccines (2009) Vol. 8, Iss. 8, pp. 1099-1107
Closed Access | Times Cited: 36
A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen
William M. Gwinn, Brandi T. Johnson, Shaun M. Kirwan, et al.
Vaccine (2013) Vol. 31, Iss. 11, pp. 1480-1489
Open Access | Times Cited: 27
Differential activation and maturation of two porcine DC populations following TLR ligand stimulation
Gaël Auray, Marina Facci, Jill van Kessel, et al.
Molecular Immunology (2010) Vol. 47, Iss. 11-12, pp. 2103-2111
Closed Access | Times Cited: 30
Exposure to Nicotine Adversely Affects the Dendritic Cell System and Compromises Host Response to Vaccination
Mahyar Nouri‐Shirazi, Elisabeth Guinet
The Journal of Immunology (2012) Vol. 188, Iss. 5, pp. 2359-2370
Open Access | Times Cited: 24
Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01
Alexander Wilkinson, Eric Lattmann, Carla B. Roces, et al.
Journal of Controlled Release (2018) Vol. 291, pp. 1-10
Open Access | Times Cited: 23
The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine
Agnese Donadei, Cristiana Balocchi, Francesca Mancini, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2016) Vol. 107, pp. 110-119
Closed Access | Times Cited: 21
Page 1 - Next Page

Scroll to top